Navigation Links
Clarient Reports First Quarter 2008
Date:4/30/2008

Generates Year-over-Year Revenue Increase of 80%; Gross Profit Improves

161%; Operating Loss Declines by 96%

ALISO VIEJO, Calif., April 30 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced preliminary financial results for the first quarter ended March 31, 2008. Revenue from continuing operations was $15.9 million for the first quarter of 2008, an increase of 80 percent compared to $8.8 million in the comparable period in 2007. Revenue from continuing operations consists of revenue from Clarient's core diagnostic services business. A combination of the service mix distribution, increases in the Medicare fee schedule and increased overall volume resulted in a 29 percent sequential revenue growth over the fourth quarter of 2007. Adjusted EBITDA (defined below) for the first quarter ended March 31, 2008 was $1.0 million, compared to Adjusted EBITDA loss of $1.8 million in the first quarter of 2007. The first quarter of 2008 marks the 15th consecutive quarter that Clarient has experienced sequential quarterly growth and reflects the highest quarter-over-quarter sequential growth rate in more than two years.

"The results of first quarter were excellent in terms of our commercial, operational and financial metrics," Clarient CEO Ron Andrews said. "We saw greater than expected strength in new customer acquisitions, reimbursement and existing customer volumes. Our continued effort to expand our presence in the leukemia and lymphoma market has helped accelerate our sequential quarter-over-quarter growth momentum in this strategically important business line. Whe
'/>"/>

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
2. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
3. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
4. Clarient Generates 52% Revenue Increase in Third Quarter 2007
5. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
6. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
7. Clarient to Present at the UBS 2007 Global Life Sciences Conference
8. J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers
9. Garmin Reports Record First Quarter; Strong Margins and Increased Market Share
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
(Date:10/31/2014)... 2014 The Suspension Revolution review published ... was developed by Dan Long, a suspension training specialist. ... fitness professional and life coach. The author of this ... muscles is not impossible , The Suspension Revolution review ... Suspension training promises efficiency when it comes to burning ...
(Date:10/31/2014)... October 31, 2014 North Shore Eye ... Garden City, Long Island and the addition of leading ... staff, according to North Shore Eye Care Medical Director, ... Acting Chairman of the Department of Ophthalmology of Winthrop-University ... in Garden City for more than 30 years. He ...
(Date:10/31/2014)... Beach, Florida (PRWEB) October 31, 2014 ... or, the “Company”) today announced it has signed a ... Canada-based companies in the urban cultivation sector - Urban ... (BC Northern Lights”), and W3 Metal Inc. (“W3 Metal” ... the “Target Companies”). Pursuant to the LOI and ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
Breaking Medicine News(10 mins):Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... cancer of the eye need not have to remove their ... The results of the Collaborative ocular Melanoma ... found that survival rates were the same regardless of whether ... radiation therapy.// , Davidorf, Professor ...
... affects women in their 30s and 40s, especially women.The illness ... cause pain, inflammation and joint destruction. , ... condition, but one third of the patients discontinue treatment early ... taking Methotrexate are prone for their drug-related liver damage .This ...
... exercise can improve their health or it would not make a ... Consensus statements published by the American College of ... researchers often can't tell how much health-improvement pay-off will result from ... make a difference at all. , , ...
... levels is becoming an increasingly important part of a medical ... or 'good' cholesterol) levels should be high, and low density ... At Johns Hopkins ... to measure non-HDL cholesterol too. This is the difference between ...
... to kill the deadly Hepatitis E virus has been designed by ... would kill the virus by cutting RNA. , , ... animals. The cloned virus could also be used for diagnostic purposes ... For this, the team had produced ...
... in tomato products, such as tomato sauce and ketchup, have ... especially prostate cancer, but the reason for such an action ... that lycopene, which is found in tomato products and other ... and treating the disease in its earliest stages.// ...
Cached Medicine News:Health News:How much can exercise improve health? 2Health News:Protective effects of tomatoes in prostate cancer 2
(Date:10/31/2014)... , Oct. 31, 2014  Digirad Corporation (Nasdaq: ... PDI, Inc. (Nasdaq: PDII ), a healthcare ... Digirad,s proposal to acquire the company.  ... discussions regarding a transaction and to operate in the ... cash, or take on additional debt, on acquisitions or ...
(Date:10/31/2014)... Oct. 31, 2014  Semler Scientific, Inc. (Nasdaq: ... risk assessment company that develops patented products that ... chronic diseases, today reported financial results for the ... 2014. "In the third quarter ... Murphy-Chutorian , M.D., chief executive officer of Semler.  ...
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5
... of a new cytokine called IL-35 could allow clinicians ... response, MEMPHIS, Tenn., Nov. 21 Investigators at ... molecule,that prevents immune responses from running amok and damaging ... new treatments for cancer, using,vaccines; for autoimmune diseases, such ...
... Nov. 20 A new study,released by Indiana ... in immediate and significant improvements in heart,health, particularly ... decrease in,hospital admissions for heart attacks, also known ... prior cardiac history in Monroe,County, Indiana versus the ...
Cached Medicine Technology:St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases 2Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows 2
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
... L.E.D. is mounted coaxially on the loupe ... battery pack giving 4 hours continuous use. ... and a charging unit that can hold ... as being a convenient container to keep ...
The PDM utilizes the latest technology for measuring interpupillary distance and left/right pupil-to-nose distance. Lightweight and easy-to-use, the PDM provides accurate and repeatable PD measuremen...
Inquire...
Medicine Products: